GlassScriptPhysician profile
Kathleen Khan
NPI 1043536394
$1,921.74
in general payments reported to CMS, 2019-2025
32 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $288 · 2021: $452 · 2022: $177 · 2023: $208 · 2024: $170 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $357.96 | 2019-2023 | |
| Pfizer INC. | $182.96 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.69 | 2019-2025 | |
| Hologic Sales and Service, LLC | $107.72 | 2019-2024 | Fetal Fibronectin Enzyme Immunoassay, Aptima |
| Aspira Women'S Health INC | $106.54 | 2021-2022 | |
| Therapeuticsmd, INC. | $105.76 | 2019-2021 | |
| Millicent US INC | $100.45 | 2019-2025 | Femlyv, Intrarosa |
| Integra Lifesciences Corporation | $81.71 | 2023 | Biofix, Biodfactor, Biodoptix |
| Amgen INC. | $67.88 | 2019-2025 | Evenity, Prolia |
| Coopersurgical, INC. | $61.91 | 2019-2024 | Paragard T 380a, Endosee |
| Exeltis, USA INC. | $59.85 | 2019-2021 | |
| Medtronic, INC. | $55.74 | 2021-2024 | Interstim |
| Astellas Pharma US INC | $54.38 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $43.40 | 2024-2025 | |
| Caldera Medical, INC | $42.40 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $40.97 | 2019-2021 | |
| Baxter Healthcare | $39.45 | 2025 | Perclot |
| Lsi Solutions INC | $36.00 | 2021-2023 | Ti Knot, Running Device |
| Becton, Dickinson and Company | $31.04 | 2025 | Arista |
| Avion Pharmaceuticals | $28.83 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $27.46 | 2019-2020 | |
| Evofem Biosciences, INC. | $17.79 | 2023 | Phexxi |
| Smith+Nephew, INC. | $17.73 | 2025 | Pico 14 |
| Mission Pharmacal Company | $16.88 | 2021 | |
| Amag Pharmaceuticals, INC. | $16.26 | 2019 | |
| Organon LLC | $16.13 | 2024 | |
| Avanos Medical | $15.74 | 2019 | |
| Medicem INC. | $15.67 | 2021 | |
| Covidien LP | $15.21 | 2019 | |
| Merck Sharp & Dohme LLC | $14.46 | 2024 | Gardasil, Gardasil 9 |
| Meditrina | $14.24 | 2019 | |
| Myovant Sciences INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.